Objective: This is the first clinical trial for Japanese to evaluate the dose -response and determine the clinically effective dose of darbepoetin alfa by weekly subcutaneously administration in anemic patients with lung cancer or ovarian cancer receiving chemotherapy. Methods: Eligible patients were required to have anemia (hemoglobin level of 11.0 g/dl). Patients were randomized in a 1:1:1 ratio to receive darbepoetin alfa (1.0, 2.25 or 4.5 mg/ kg) subcutaneously once a week for up to 12 weeks. The study drug was withheld from patients who had a hemoglobin level .15.0 g/dl (for men) or 14.0 g/dl (for women), and reinstated at 50% of the previous weekly dose when the hemoglobin level decreased to 13.0 g/dl. Quality-of-life assessments were conducted using the Japanese version of the Functional Assessment of Cancer Therapy-anemia (FACT-an) questionnaire. Results: Hemoglobin response rate was 31.6%, 55.6% and 70.3% in 1.0, 2.25 and 4.5 mg/kg groups, respectively. The dosages of 2.25 and 4.5 mg/kg thus met the clinically effective dose criterion of at least 50% of patients achieving a hemoglobin response. The FACT-fatigue subscale had a high internal consistency with Cronbach's a score. Although no improvement in FACT-fatigue subscale score from baseline to the end of the treatment phase was confirmed for any dose group, there was a correlation between FACT-fatigue subscale score and hemoglobin concentration. Darbepoetin alfa appears to be well tolerated in this setting and no dose-dependent adverse events were observed. Conclusions: Darbepoetin alfa alleviated anemia caused by platinum-based chemotherapy, and the dosage of 2.25 mg/kg was the lowest dose that met the clinically effective dose criteria when administered once weekly.
INTRODUCTION
Anemia is a frequent complication in cancer patients receiving multicycle chemotherapy. Anemia is associated with a plethora of symptoms, including fatigue and dyspnea. Fatigue is the most frequently reported symptom in patients with cancer and has been found to have severe detrimental effects on their lives (1) . The etiology of anemia is multifactorial (2 -4) . In particular, direct effects on the renal tubules by platinum-based compounds lead to a decrease in the production of erythropoietin (EPO), which is responsible for terminal differentiation, proliferation and survival of red blood cell (RBC) precursors (5) . If a patient with cancer develops severe or symptomatic anemia, RBC transfusions may be required, with their attendant risks. Acute transfusion reactions can occur, and although the blood supply is now safer with respect to infection than before, the risk of transmission of infectious agents still exists (6, 7) . In addition, there are some concerns that frequent RBC transfusions with allogeneic blood may adversely affect the immune system of patients with cancer, thereby increasing the tendency to develop infections and hastening the time to relapse or shortening survival (8) .
Erythropoiesis-stimulating agents (ESAs), such as recombinant human EPO (rHuEPO) or darbepoetin alfa (DA), have provided another treatment option for anemic patients with cancer receiving chemotherapy and have been shown to reduce the need for transfusions in this setting (9, 10) . Previous studies have indicated that ESAs increase hemoglobin (Hb) concentration, relieve the symptoms of anemia, improve quality of life (QOL) and reduce transfusion requirements in patients with solid tumors (11) or lymphoproliferative malignancies (12) (13) (14) .
DA is a unique EPO protein with higher sialic acid content, longer terminal half-life and higher biological activity than rHuEPO (15) , allowing less frequent administration with a similar efficacy and safety profile (16 -18) . Previous studies of DA have demonstrated that it is effective for the treatment of anemia across a wide range of tumor types, with a similar dose -response curve observed in nonmyeloid malignancies (19) . Furthermore, in foreign countries, a Phase 3, randomized, double-blind, placebocontrolled study conducted on patients with lung cancer receiving chemotherapy confirmed that a DA starting dose of 2.25 mg/kg administered once weekly (QW) significantly reduced the percentage of patients who required an RBC transfusion and increased Hb concentrations compared with a placebo (10) .
In Europe and the USA, ESAs have been widely used since the 1990s for the treatment of chemotherapyinduced anemia. However, they have not been approved yet in Japan. In this prospective study, we first planned a Phase 2 dose-finding study of QW dosing of DA in patients with lung or ovarian cancer who were expected to receive cyclic platinum-containing chemotherapy once every 3 or 4 weeks.
PATIENTS AND METHODS

STUDY POPULATION
The protocol was approved by the institutional review boards of each of the 31 participating centers, and all patients gave written informed consent before any study-related procedures were carried out.
For entry into the study, patients were required to have been diagnosed with lung or ovarian cancer and expected to receive cyclic platinum-containing chemotherapy once every 3 or 4 weeks for at least two courses after enrollment. Eligible patients were 20 -74 years of age and were required to have anemia (Hb level of 11.0 g/dl). Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2, and adequate hepatic and renal functions.
Patients were excluded if they were iron deficient; had primary or metastatic malignancy of the central nervous system; had a thrombotic tendency; had received more than three RBC transfusions within 4 weeks or any RBC transfusions within 2 weeks of randomization; were pregnant, breastfeeding or not using adequate birth control measures; or had a history of seizure disorders, active cardiac disease, uncontrolled hypertension, active infection or inflammation or a primary hematologic disorder as the cause of their present anemia.
STUDY DESIGN AND TREATMENT SCHEDULE
This study was a Phase 2, multicenter, randomized, openlabel, sequential dose-finding study (Fig. 1) . DA (Kyowa Hakko Kirin Co., Ltd, Japan) was supplied in vials as a clear, colorless, sterile protein solution containing 500 mg/ml of the drug.
After registration, patients were randomized in a 1:1:1 ratio to receive DA (1.0, 2.25 or 4.5 mg/kg) subcutaneously once a week for up to 12 weeks, with a 2-week follow-up period after the last dose of DA. Randomization was performed using a central computerized system and was stratified to balance the treatment groups with respect to tumor type (lung cancer, ovarian cancer), Hb level (,9.0, 9.0 Hb level , 10.0 and 10.0 g/dl) and treatment site. The patients received the first dose of DA on the first day of a chemotherapy cycle.
The study drug was withheld from patients who had an Hb level of .15 g/dl (for men) or 14 g/dl (for women), and reinstated at 50% of the previous weekly dose once the Hb concentration decreased to 13.0 g/dl. Patients with a serum ferritin concentration of ,10 ng/ml or a serum transferrin saturation of ,15% received iron therapy to prevent iron deficiency.
RBC transfusion policies were left to the discretion of the investigators, although RBC transfusions were recommended for patients with an Hb level of 8.0 g/dl or symptoms of anemia, regardless of the patient's Hb level.
STUDY ENDPOINTS
The primary objective of this study was to determine the clinically effective dose (CED) of DA. The criteria for CED are shown in Table 1 .
Efficacy was assessed using Hb endpoints and the incidence of RBC transfusions. The primary measure of efficacy was the percentage of patients achieving an Hb response, defined as an increase in Hb of 2.0 g/dl from the baseline
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Weekly darbepoetin alfa alleviated anemia in the absence of any RBC transfusions during the previous 28 days. The secondary efficacy endpoints were the change in Hb concentration from baseline during the treatment and the incidence of RBC transfusions. QOL assessments were conducted at baseline, during 7 -11 weeks, at the beginning of a chemotherapy course and at the end of a treatment phase after the initiation of DA administration. The Japanese version of the Functional Assessment of Cancer Therapy-anemia (FACT-an) questionnaire was used, which is composed of the FACT-general, a 20-item FACT-anemia subscale and 13 items of which make up the FACT-fatigue subscale.
The safety of DA was evaluated by monitoring adverse events, Hb level, changes in laboratory values and vital signs, and antibody formation resulting from DA administration.
STATISTICAL ANALYSIS
The efficacy analyses were conducted using a per-protocol set that included all patients who received seven or more doses of the study drug and at least two courses of platinum-containing chemotherapy, without major protocol deviations. The proportion of patients exhibiting an Hb response was estimated by subtracting the Kaplan -Meier estimate of the survivor function during week 1 until the end of treatment phase in the absence of an RBC transfusion during the previous 28 days with 95% confidence intervals (CIs), because of the anticipated withdrawal rate. The same analysis for patients in the FAS and analysis using a crude proportion were also performed as part of the sensitivity analysis. For secondary analysis, the percentage of patients exhibiting an Hb correction and patients who received at least one RBC transfusion were also estimated using the Kaplan -Meier method. Cronbach's a coefficient was calculated to assess the reliability of the FACT-an scales. Summary statistics by Hb levels were used to assess the validity of FACT-an scales.
Safety analyses were conducted on all patients who received at least one dose of the study drug. Adverse events were summarized by primary system organ class and by preferred term.
Baseline demographic and clinical characteristics were summarized by the summary statistics.
This study was determined to require a sample size of 120 patients ( 40 patients in each dose cohort accounting for patients with drop-out). With 30 patients evaluated in each dose cohort, the proportion of Hb response could be estimated within a standard error of 0.09 if the true proportion is almost 50%.
RESULTS
PATIENT DEMOGRAPHICS AND DISPOSITION
Of the 145 patients screened, 132 were enrolled into the study and randomized. Four patients withdrew from the study before receiving the first dose of the study drug. One Jpn J Clin Oncol 2010;40 (6) 523 hundred and twenty-eight patients (42 patients in the 1.0 mg/kg group and 43 patients in each of the 2.25 and 4.5 mg/kg groups) received at least one dose of the study drug. Twenty-two patients (12 patients received less than seven doses of the study drug, 9 patients received less than two courses of platinum-containing chemotherapy and 1 patient did not have laboratory data after administration) were excluded from the efficacy evaluation due to protocol deviations. One hundred and six patients (33 patients in the 1.0 mg/kg group, 36 patients in the 2.25 mg/kg group and 37 patients in the 4.5 mg/kg group) were included for all efficacy endpoints. Demographic characteristics were similar among the groups, except for age ( Table 2 ).
EFFICACY
The proportion of patients that exhibited an Hb response is shown in Fig. 2 (Fig. 3) . Although, in this study, there was no difference in the mean change in Hb concentration between the 2.25 and 4.5 mg/kg groups, a trend toward greater increases in Hb level with higher doses of DA was observed: the increase was 0.71 g/dl in the 1.0 mg/kg cohort compared with 1.71 g/dl in the 2.25 mg/kg and 1.72 g/dl in the 4.5 mg/kg cohorts at the end of the treatment phase. Of the 128 patients, FACT-fatigue subscale score data were available for 127 (41 patients in the 1.0 mg/kg group and 43 patients in each of the 2.25 and 4.5 mg/kg groups). The Japanese version of the FACT-fatigue subscale score had a high internal consistency with Cronbach's a score, which was 0.908 at baseline and 0.932 at the end of the treatment phase. In this study, although no improvement in FACT-fatigue subscale score from baseline to the end of the treatment phase was observed for any dose group, FACT-fatigue subscale score was correlated with Hb concentration at the end of the treatment phase (Fig. 4) . In addition, subscale score was also correlated with ECOG performance status score.
SAFETY
The incidence of adverse events that were considered by the investigators to be related to the study drug was similar among the cohorts: 15 patients (35.7%) in the 1.0 mg/kg group, 15 patients (34.9%) in the 2.25 mg/kg group and 15 patients (34.9%) in the 4.5 mg/kg group. The most frequently reported event was headache [one patient (2.4%) in the 1.0 mg/kg group, two patients (4.7%) in the 2.25 mg/kg group and three patients (7.0%) in the 4.5 mg/kg group]. Other treatment-related adverse events seen in two or more patients were sporadic in each dose cohort ( Table 3 ). The treatment-related adverse events of Grade 3 or greater were angina, sudden hearing, adrenal hemorrhage, nausea, fatigue, increased blood pressure, increased blood uric acid, hypernatremia and prostate induration and each of them was observed in one patient. The incidences of serious adverse events and adverse events of Grade 3 or greater that were considered by the investigators to be related to the study drug were also similar in each dose cohort: three patients in each dose cohort (7.1% in the 1.0 mg/kg group, 7.0% in the 2.25 mg/kg group and 7.0% in the 4.5 mg/kg group). The incidence of adverse events regardless of relationship was at a level expected in a population of cancer patients receiving chemotherapy and occurred at a similar frequency within each dose cohort. The incidences of serious adverse events and adverse events of Grade 3 or greater were similar in each dose cohort.
The percentage of patients who exceeded the Hb thresholds (14.0 g/dl for women and 15.0 g/dl for men) was under 20% Jpn J Clin Oncol 2010;40 (6) 525 in each cohort [one patient (2.4%) in the 1.0 mg/kg group, four patients (9.3%) in the 2.25 mg/kg group and six patients (14.0%) in the 4.5 mg/kg group]. Five patients (3.9%) [two patients (4.8%) in the 1.0 mg/kg group, two patients (4.7%) in the 2.25 mg/kg group and one patient (2.3%) in the 4.5 mg/kg group] died during the study, but none of the deaths were considered by the investigators to be related to the study drug. One venous thromboembolism, a renal vein thrombosis (Grade 1), was observed in one patient with ovarian cancer in 1.0 mg/kg group (2.4%). No anti-DA antibodies were detected in this population of patients receiving DA.
DISCUSSION
In this study, the proportion of patients who exhibited a 2.0 g/dl increase in Hb level from baseline was investigated. Dosages of both 2.25 and 4.5 mg/kg met the CED criterion, although there was no reduction in the median time to Hb response at 4.5 mg/kg group compared with 2.25 mg/kg group (10 weeks for the 2.25 mg/kg group and 13 weeks for the 4.5 mg/kg group). Meanwhile, in a study in the US study, there was an obvious dose-dependent increase in the percentage of patients exhibiting an Hb response at 4.5 mg/kg group compared with 2.25 mg/kg group (18) . In this study, the median numbers of doses administered were 12, 10 and 9 in the 1.0, 2.25 and 4.5 mg/kg groups, respectively. The median number of doses in the 4.5 mg/kg group was smaller than that in the other groups irrespective of safety. There was no dose-dependent difference in the number of subjects not completing the study. This discrepancy in dose-dependency between the US study and this study may be related to the fact that the treatment duration in Table 3 . Adverse events related to study drug reported for two or more patients receiving darbepoetin alfa (safety analysis population) Event (PT) Darbepoetin alfa Total (n ¼ 128) Values are expressed as n (%). PT, preferred term. 
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Weekly darbepoetin alfa alleviated anemia the 4.5 mg/kg group of this study was shorter than that for other groups. The incidence of RBC transfusions was assessed throughout the study. The period from week 5 to the end of the treatment phase in patients receiving at least one RBC transfusion was analyzed (14) . The percentage of patients who received at least one RBC transfusion was lower in the 2.25 mg/kg group than in the other groups from week 5 to the end of the treatment phase, although there was no significant difference. It has been reported that onceweekly DA treatment reduced the percentage of patients receiving RBC transfusions (18) . The enrollment of more subjects is considered necessary to assess the reduction in transfusion rate, because this study was designed to assess the percentage Hb response as the primary endpoint. Further large-scale studies focusing on RBC transfusion are needed in Japan.
ESAs have been shown to improve health-related QOL in several studies (20 -22) . A FACT-an questionnaire was used widely to evaluate cancer patients with anemia, but there are few Japanese reports of studies conducted using FACT-an. Therefore, in this study, the feasibility, reliability and validity of the FACT-an questionnaire were assessed. The collection rate of questionnaires was nearly 100%. FACT-fatigue showed a higher internal consistency (Cronbach's a score range ¼ 0.908 and 0.932 before and after treatment) than other subscales. This internal consistency was consistent with previously reported results and other subscales as well (23) . Investigation of the correlation between QOL score and Hb level with FACT-fatigue and FACT-an showed a trend of higher QOL score with increasing Hb level as well as a validation study of FACT (24) . These results indicated that the use of the FACT-an questionnaire was a feasible, reliable and valid method of assessing anemia and fatigue in Japanese cancer patients.
In a US study, QOL score increased with increasing Hb concentration (18) . In this study, no correlation between FACT-fatigue score and Hb concentration was found. Reasons may include that the QOL baseline score for Japanese patients is slightly higher than for others. A meta-analysis indicated that the baseline of FACT-fatigue is about 26, but in this study, the baseline is 36, which reflects less fatigue (25) . A high baseline score may affect the efficacy's resistance to the change in QOL score. FACT-fatigue uses the minimum important difference (MID). MID is the 'smallest difference in score in the domain of interest that patients perceive as important, either beneficial or harmful, and that would lead a clinician to consider a change in the patient's management'. Because FACT-fatigue MID is already known as 3 -4, characteristics may have been different between this study and those described in existing reports (26) . This baseline difference in Japanese patients may cause difficulty for interpretation.
The results from this study suggest that DA is safe when administered to patients with anemia who are undergoing chemotherapy. The adverse event profile was dominated by findings, e.g. neutropenia, nausea, and vomiting, that are predictable in a population of patients with advanced malignancy receiving multicycle chemotherapy. No unexpected trends were noted in the incidence or severity of adverse events. Although the correlation between the rate of Hb concentration increase and adverse events was investigated, no relationship was apparent. Specifically, the incidence of hypertension and thrombotic events was reported to be associated with a rapid Hb concentration increase in patients with renal failure undergoing dialysis. In this study, the incidence of these complications in all patients was not associated with a rapid increase in Hb concentration. ESA-associated pure red cell aplasia cases have been reported, but almost all cases were observed among hemodialysis patients who received several months of one type of subcutaneously administered rHuEPO (Eprex; Johnson & Johonson, New Brunswick, NJ) (27) . No evidence of antibodies to DA was detected for any patient in this study.
Several reports suggested that ESAs had a potential to increase the risk of mortality and/or disease control (28 -35) and the negative safety signals were incorporated into the product labels in a boxed warning. It should also be noted that the recently published meta-analyses have indicated a negative impact of ESA use on mortality in cancer patients but the increases on mortality or disease progression were not detected in the patients with chemotherapy-induced anemia (36 -39) . Several non-clinical studies also have indicated that ESAs do not promote the tumor growth and improve chemotherapeutic outcome in cancer-bearing animals (40 -42) . Therefore, Aapro and Spivak (43) suggested that the benefit of ESAs outweighs their risks when used for labeled indication and guidelines. The impact of ESAs on mortality and/or disease progression could not be assessed since a long-term follow-up surveillance was not planned in this study. Therefore, further research is needed to clarify the increased risk of them in Japanese patients with chemotherapy-induced anemia.
In conclusion, DA was effective and well tolerated for the treatment of anemia in patients with lung or ovarian cancer receiving platinum-containing chemotherapy and dosages of DA 2.25 mg/kg/QW were the lowest dose that met the CED criteria. Therefore, dosage of DA 2.25 mg/kg/QW was determined as a recommended dose for randomized, placebocontrolled, Phase 3 trial in Japan.
